Rallybio Corporation
RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Tā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.63
Price-2.11%
-$0.01
1Y
Price
Market Cap
$26.129m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-4743.9%
EBITDA Margin-4576.9%
Net Profit Margin-3952.4%
Free Cash Flow MarginRevenue
$761k
+19.7%
1y CAGR+6.6%
3y CAGR+4.9%
5y CAGREarnings
-$41.652m
+27.9%
1y CAGR+12.8%
3y CAGR-0.8%
5y CAGREPS
-$0.94
+29.3%
1y CAGR+23.0%
3y CAGR+6.5%
5y CAGRBook Value
$45.964m
$51.003m
Assets$5.039m
Liabilities$58k
DebtDebt to Assets
0.1%
-
Debt to EBITDAFree Cash Flow
-$41.991m
+14.8%
1y CAGR+9.3%
3y CAGR+0.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company